Ms200647_0046- Safety Study Of Bintrafusp Alfa In Combination With Other Anti-Cancer Therapies In Participants With Locally Advanced Or Advanced Cervical Cancer
Posted Date: May 5, 2021
- Investigator: Amanda Jackson
- Specialties: Cancer, Cervical Cancer, Gynecologic Oncology, Oncology
- Type of Study: Drug
The purpose of this study is to evaluate the safety and tolerability of bintrafusp alfa in combination with other anti-cancer therapies in participants with locally advanced or advanced cervical cancer. The primary outcome measured will be the incidence of Dose limiting toxicities.
Criteria:
Documented Evidence Of Cervical Adenocarcinoma, Squamous Cell Carcinoma, Or Adenosquamous Carcinoma, Ecog 0-1, Life Expectancy >12 Weeks, Adequate Hematological, Hepatic, Renal And Coagulation Function, No Previous Organ Transplant, No Significant Or Chronic Infection, No Active Central Nervous System (Cns) Metastasis, No Clinically Significant Cardiovascular/Cerebrovascular Disease, No Prior Cancer Treatment With Any Other Immunotherapy Or Checkpoint Inhibitors Or Any Other Immune-Modulating Monoclonal Antibody
Keywords:
Cervical Cancer
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com